opiod dependence and overdose

Opioid Dependence & Overdose Management Notes
Contents

  • Opioid dependence management

    • Withdrawal syndromes

    • Methadone

    • Buprenorphine

    • Naltrexone

  • Opioid overdose management

    • Activated charcoal

    • Naloxone

Learning Outcomes

  • Accurately describe the symptoms of opioid withdrawal and their clinical presentations.

  • Understand the roles of various drugs in managing opioid dependence and apply that knowledge clinically.

  • Discuss the pharmacology of medications used in opioid dependence management.

  • Recognize the symptoms of opioid overdose and their clinical manifestations.

  • Describe management strategies for opioid overdoses in clinical settings.

  • Explain the pharmacology of drugs used in managing opioid overdose.

Opioid Dependence & Its Management

Effects of Acute & Chronic Opioid Receptor (OR) Stimulation

  • Desensitization: Continuous stimulation of opioid receptors (ORs) leads to a reduction in responsiveness, diminishing their effectiveness over time, resulting in decreased analgesic response.

  • Tolerance: This phenomenon causes users to require progressively higher doses to achieve the same level of pain relief or euphoria, contributing to a potential increase in misuse and overdose risk.

  • Dependence: A state wherein the absence of the drug precipitates withdrawal symptoms, which can be physically and psychologically distressing, thus complicating cessation efforts.

  • Addiction: Characterized as a chronic, relapsing disorder, addiction is marked by compulsive drug seeking and use despite the harmful consequences, alongside neurobiological changes affecting decision-making and behavior.

Withdrawal Aetiology

  • Mechanism: Opioid receptors (ORs), classified as G protein-coupled receptors, inhibit adenylyl cyclase, leading to decreased cyclic adenosine monophosphate (cAMP) levels, which reduces neuronal excitability. When opioid use is halted, this suppression is lifted, resulting in increased neuronal activity and withdrawal symptoms.

  • Withdrawal Symptoms: These arise from the disinhibition of central nervous system (CNS) pathways, which becomes evident after cessation of opioid use, manifesting as various physical and psychological symptoms, referred to as "super-activation" of the CNS.

  • Specific Brain Sites:

    • The locus coeruleus plays a pivotal role in opioid withdrawal syndrome; it primarily regulates noradrenergic activity and has a dense presence of opioid receptors.

    • Opioids normally inhibit the excitatory neurotransmission in this area, and withdrawal elicits increased norepinephrine (NA) release, contributing to withdrawal symptoms.

Withdrawal Symptoms

  • Commonly experienced withdrawal symptoms include:

    • Nausea & vomiting

    • Sweating

    • Myalgias (muscle pain)

    • Arthralgias (joint pain)

    • Chills and shivering

    • Rhinorrhea (runny nose)

    • Agitation and anxiety

    • Dilated pupils

    • Abdominal cramps and pain

    • Tachycardia (increased heart rate)

    • Hypertension (raised blood pressure)

    • Diarrhea, which can lead to severe dehydration if not managed

Drugs Used in the Management of Opioid Dependence

  • Methadone:

    • A long-acting synthetic opioid with full agonist properties primarily targeting mu-opioid receptors (MORs), effective for both managing pain and aiding in addiction treatment across settings.

  • Buprenorphine:

    • A unique medication that acts as a partial agonist at MORs and exhibits interactions with kappa-opioid receptors (KOR) and delta-opioid receptors (DOR), thus enabling relief from withdrawal symptoms while minimizing overdose potential.

  • Naltrexone:

    • Primarily functions as an opioid antagonist at MORs, reducing the euphoric effects of opioids and preventing relapse in recovering individuals.

Methadone

  • Properties: Methadone is structurally similar to morphine; however, it presents a racemic mixture consisting of:

    • L-methadone: More effective for analgesia while having a lower risk of respiratory depression than full agonists, and it exhibits antitussive properties.

    • D-methadone: Less potent, primarily contributing to its analgesic effects.

Methadone - Absorption

  • Methadone is well absorbed via the gastrointestinal tract (GIT). Plasma concentrations are detectable within 30 minutes, reaching peak levels around 4 hours post-administration. Intramuscular (IM) or subcutaneous (SC) injections lead to concentrated delivery to the brain within 1-2 hours due to rapid absorption mechanisms.

  • Its low hepatic first-pass metabolism enhances its bioavailability, making it effective for oral and parenteral administration.

Methadone - Distribution

  • The drug's half-life (T1/2) spans between 15 to 40 hours, leading to prolonged effects and a potential build-up of plasma concentration, especially during the early withdrawal phase where the drug is released from body fat and tissue compartments.

  • The slow release results in a mild yet protracted withdrawal syndrome, complicating cessation attempts.

Methadone – Metabolism & Elimination

  • Metabolism: Occurs predominantly in the liver; careful monitoring is warranted in patients with hepatic insufficiency due to the risk of accumulating active drug metabolites.

  • Elimination: Primarily through renal pathways, with some minor biliary excretion; urinary excretion is influenced by the nature of urine (acidification increases elimination). A dose reduction may be necessary if the estimated glomerular filtration rate (eGFR) falls below 10 mL/min.

Methadone – Side Effects & Drug Interactions

  • Methadone exhibits side effects akin to morphine with reduced potential for addiction; it can prolong the QT interval, raising concerns when co-administered with other drugs affecting cardiac rhythm.

  • Drug Interactions: Medications such as rifampicin and phenytoin can enhance the metabolism of methadone, risking withdrawal symptoms and loss of analgesic effectiveness.

Methadone – Uses

  • Patient eligibility includes confirmed opioid dependence, with management strictly regulated within certified treatment programs.

  • Dosage guidelines dictate:

    • Withdrawal Management: Initiate at 10-30 mg/day, adjusting by 10-20% daily over a week.

    • Opioid Substitution Treatment: Start between 10-30 mg/day with careful titration to avert withdrawal.

    • Chronic Pain Management: Ranging from 2.5-10 mg every 8-12 hours based on individual need.

Buprenorphine

  • Characteristics: As a partial agonist at MORs, buprenorphine possesses significant analgesic potency, surpassing that of morphine, coupled with unique pharmacological properties.

Buprenorphine – Unique Features

  • Its partial agonistic effect at MORs leads to:

    • High receptor affinity resulting in a gradual dissociation from receptors, alleviating withdrawal symptoms more comfortably.

    • An analgesic ceiling effect reducing overdose risks at elevated doses, contributing to a superior safety profile compared to full agonists.

Buprenorphine – Absorption & Distribution

  • Absorption: Poor oral bioavailability due to extensive first-pass metabolism; sublingual administration is preferred for achieving peak plasma levels within 3-4 hours.

  • Distribution: Highly lipophilic, enabling rapid entry across the blood-brain barrier (BBB). Approximately 96% protein binding alters its pharmacodynamic effects and therapeutic outcomes.

Buprenorphine – Metabolism & Elimination

  • Metabolism: Undergoes significant transformation through CYP3A4 pathways with the resulting metabolite norbuprenorphine exhibiting minimal intrinsic activity compared to its parent drug.

  • Excretion: Primarily eliminated through renal channels, with less than 20% removed unchanged, while most is expelled through feces.

Buprenorphine – Uses

  • Maintenance Therapy: Effective and preferred for treating opioid dependence, necessitating caution when also prescribing full opioid agonists to prevent withdrawal crisis; it is advised to taper agonist doses before initiation.

  • Detoxification: Can be administered singularly or in combination with naloxone to mitigate misuse potential.

Naltrexone

  • Serves as an opioid antagonist predominantly at MORs, with lesser antagonistic efficacy at DORs and KORs, though the clinical ramifications are uncertain.

  • Utilized to maintain abstinence in patients previously opioid-free for at least 7-10 days, also effective in treating alcohol dependence by blocking opioid receptors and preventing physiological dependence and intoxication effects.

Naltrexone – Side Effects & Drug Interactions

  • Side Effects: Commonly experienced adverse effects include gastrointestinal irritations such as diarrhea, nausea, abdominal cramps, headache, anxiety, elevated blood pressure, muscle pain, and fatigue.

  • Drug Interactions: Co-administration with thioridazine heightens lethargy risk, warranting close monitoring.

Naltrexone – Cautions

  • Dosage adjustments should be considered for individuals with hepatic or renal impairments; risks during pregnancy must be evaluated due to potential fetal implications. Special consideration is warranted in prescribing to geriatric patients and for pediatric uses due to safety uncertainties.

Opioid Overdose Management

Symptoms of Opioid Overdose

  • Respiratory depression is the primary life-threatening manifestation, leading to reduced respiratory effort, cyanosis, and potential asphyxia.

  • CNS impacts encompass a spectrum from mild sedation to profound coma; companion symptoms may include hypotension, hypothermia, and altered pupil response—from miosis to mydriasis based on hypoxia severity—and various motor symptoms including muscle rigidity and twitching.

  • Non-cardiogenic pulmonary edema may develop suddenly and can be notably delayed, particularly following recovery phases from overdose.

  • Reduced gastrointestinal motility can result in ileus, contributing to further complications in overdose scenarios.

Management Steps

  • Initiate gastric lavage and administer activated charcoal only if:

    • The opioid was ingested within 1-2 hours prior to treatment.

    • A significant quantity of opioids was consumed.

  • Immediate attention to ventilatory support is critical; this may require manual ventilation support for the patient.

  • Naloxone, representing a crucial opioid antagonist, should be promptly administered to reverse overdose effects.

Activated Charcoal

  • Mechanism: Acts by adsorbing various toxic substances, thus limiting their systemic absorption from the GIT following overdose.

  • Limitations: Ineffectiveness is noted against corrosive agents and strong acids or alkalis.

  • Administration: Typically formulated as a slurry of 50-100 g mixed in 400-800 mL water; nasogastric (NG) tube delivery is common.

  • Multiple-Dose Activated Charcoal (MDAC): Administering multiple doses can facilitate enhanced elimination of certain dangerous drugs and is useful for cases involving specific overdoses such as carbamazepine, phenobarbital, and others.

Naloxone – General Information

  • An opioid antagonist with a high binding affinity for MORs, Naloxone acts rapidly when administered intravenously within a minute of exposure.

  • Displays a half-life of approximately 30 minutes when given by IV, necessitating repeated dosages amid long-acting opioid overdoses to sustain the reversal effects.

  • Withdrawal symptoms may manifest due to its actions in chronic opioid users, emphasizing careful monitoring during administration.

Management of Opioid Overdose

  • Adult Dosing:

    • Initial IV dose set at 0.4 - 2 mg, repeatable every 2-3 minutes until a maximum of 10 mg has been administered without improvement.

    • In severe overdose cases, such as massive heroin ingestions, continuous infusion at 0.004 mg/mL may be required, ensuring unused doses are discarded post-24 hours.

    • Pediatric Dosing:

    • Initial IV dose of 0.01 mg/kg, with following doses tailored to patient's response.

  • Special attention should be directed to chronic opioid users where naloxone's prompt actions can precipitate withdrawal; utilize 0.01-0.05 mg IV as needed until withdrawal symptoms emerge.

  • Continuous monitoring is vital due to naloxone's shorter action relative to many opioids, highlighting the potential need for subsequent administration.

Monitoring After Naloxone Administration

  • Essential post-administration monitoring for:

    • Respiratory status and potential respiratory depression

    • Blood pressure fluctuations

    • Signs of nausea and vomiting

    • Heart rate changes and overall cardiovascular status

    • Monitoring for possible cardiac rhythms abnormalities and arrest

  • Patients require observation for at least 12 hours post-administration to ensure safety and evaluate for potential opioid re-emergence reactions.